Tagged with

France As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In France, the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) – the country’s drug regulator –…

Spain With Spain’s economy on the road to recovery after experiencing a period of financial crisis, multinational companies are once again seeing the country as a prime investment destination.   The top 20 pharmaceutical companies in Spain — combining the prescription and consumer market — in the year up to April…

Cyprus With a population of just 1.2 million and a proportionately small pharmaceutical market by EU standards, Cyprus is often overlooked as a healthcare and life sciences investment destination. However, with the island now on the road to economic recovery following the EUR ten billion IMF-ECB-EU troika bailout in 2013, an…

Turkey Philipp Haas, chairman and CEO of DEVA, discusses the company’s export strategy and current positioning in the international pharmaceutical playing field. Haas also covers the changing dynamics of the industry in the Turkish market. In crisis there is opportunity for those who are willing to take it 2018 has been…

Spain Following Bayer’s acquisition of Monsanto, a US agriculture giant, the company is facing a new era in which its pharmaceutical arm is still a highly strategic part. Bernardo Kanahuati, Bayer’s CEO for Iberia, highlights the importance of Spain’s manufacturing and R&D for Bayer International, as well as his strategy to…

France Ipsen CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come.   “From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience and…

Turkey Turgut Tokgöz, secretary general of the Pharmaceutical Manufacturers Association of Turkey (IEIS), provides his take on the state of the Turkish pharmaceutical sector, highlighting the challenges that the industry faces with domestic pricing policy, the currency crisis of the Turkish Lira, and the barriers hindering Turkish firms from entering the…

France Thierry Philip, president of Institut Curie, talks about the organization, the effect of cancer on Social Security and the need for a cohesive European plan involving all oncology research institutions and policy-makers.   The most important achievement was the accreditation as a comprehensive cancer centre by the OECI One of…

Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here he discusses the new Alma-Ata Declaration that focuses on primary care and work at…

Algeria A sudden imposition of import restrictions on pharmaceuticals in 2017 has pushed several multinational companies to establish local production facilities in Algeria. However, the localization process can be fraught both for companies that establish direct manufacturing footprints via joint ventures and those that employ the services of local contract manufacturers.…

Canada Mark Ware, the Chief Medical Officer of Canopy Growth Corporation, has intensely investigated the effects of cannabinoids, making him perfectly placed to cover this new era of cannabis in healthcare.    I propose that the renaissance of cannabis under varying regulatory frameworks actually represents a paradigm shift in health care, and…

Turkey Dr Orhan Mutlu Topal, general manager at Emre Ecza Ilac, offers an insider take on the Turkish vaccine industry, the challenges on the horizon for the Turkish pharmaceutical sector, and the country’s technology transfer from localization policies. The localization of vaccine production will be a groundbreaking achievement for Turkey. This is…